Catapult Capital Management’s Genomic Health, Inc. GHDX Stock Holding History

Catapult Capital Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-35,000	Closed	-$1.12M	–	261
2014 Q4	$1.12M	Sell	35,000 -16,627	-32%	-$541K	0.28%	104
2014 Q3	$1.46M	Buy	+51,627	New	+$1.44M	0.16%	138

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Catapult Capital Management's GHDX Position: Q1 2015 in Review

Catapult Capital Management sold out of Genomic Health, Inc. (GHDX) in Q1 2015, closing a stake of 35,000 shares — an estimated $1.12M sold.

Catapult Capital Management first reported a position in GHDX in Q3 2014 and held it in 2 quarters. The position peaked at $1.46M in Q3 2014. 112 funds tracked by Wall St. Rank hold GHDX as of Q1 2015.

Catapult Capital Management reported no remaining Genomic Health, Inc. position as of Q1 2015 after selling out during the quarter.
Catapult Capital Management sold 35,000 Genomic Health, Inc. shares in Q1 2015, an estimated $1.12M.
Catapult Capital Management first reported a position in Genomic Health, Inc. in Q3 2014 and held it in 2 quarters.
Catapult Capital Management's Genomic Health, Inc. position peaked at $1.46M in Q3 2014.
112 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2015.

Based on Catapult Capital Management's 13F filing for Q1 2015, filed 15 May 2015.